Citadel Advisors
INZY

Citadel Advisors’s Inozyme Pharma INZY Stock Holding History

Citadel Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-128,700
Closed -$515K – 13408
2025
Q2 		$515K Buy
128,700
+114,900
+833% +$285K ﹤0.01% 8560
2025
Q1 		$12.6K Buy
13,800
+11,200
+431% +$15.5K ﹤0.01% 13439
2024
Q4 		$7.2K Sell
2,600
-1,100
-30% -$4.18K ﹤0.01% 13749
2024
Q3 		$19.4K Buy
3,700
+2,200
+147% +$11.4K ﹤0.01% 12798
2024
Q2 		$6.69K Sell
1,500
-100
-6% -$485 ﹤0.01% 13314
2024
Q1 		$12.3K Sell
1,600
-3,100
-66% -$17K ﹤0.01% 13370
2023
Q4 		$20K Sell
4,700
-21,000
-82% -$74.6K ﹤0.01% 12614
2023
Q3 		$108K Buy
25,700
+22,700
+757% +$115K ﹤0.01% 10800
2023
Q2 		$16.7K Sell
3,000
-3,300
-52% -$19.5K ﹤0.01% 12884
2023
Q1 		$36.1K Buy
+6,300
New +$16.6K ﹤0.01% 12552

Citadel Advisors's INZY Position: Q3 2025 in Review

Citadel Advisors sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 35,166 shares — an estimated $141K sold.

Citadel Advisors first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $6.34M in Q3 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

  • Citadel Advisors reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 35,166 Inozyme Pharma shares in Q3 2025, an estimated $141K.
  • Citadel Advisors first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
  • Citadel Advisors's Inozyme Pharma position peaked at $6.34M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.